Biolyst › ALMSALUMIS INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 21, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 9.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 10 concluded trials, 90% reached completion rather than being terminated or withdrawn.
Track ALMS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ALMS in the tracker
Recent history
Date Event Type Phase
September 1, 2026
8-K filed: Other event Filing
—
August 13, 2026
Quarterly results filed (8-K) Earnings
—
August 10, 2026
8-K filed: Other event Filing
—
June 29, 2026
8-K filed: Other event Filing
—
June 23, 2026
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Trial Milestone
Phase 2
May 14, 2026
Quarterly results filed (8-K) Earnings
—
March 30, 2026
8-K filed: Other event Filing
—
March 24, 2026
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage Trial Milestone
Phase 1
March 19, 2026
Quarterly results filed (8-K) Earnings
—
January 9, 2026
Quarterly results filed (8-K) Earnings
—
January 6, 2026
8-K filed: Other event Filing
—
January 2, 2026
8-K filed: Other event Filing
—
November 13, 2025
Quarterly results filed (8-K) Earnings
—
September 23, 2025
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Trial Milestone
Phase 3
September 19, 2025
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Trial Milestone
Phase 3
September 3, 2025
8-K filed: Other event Filing
—
August 13, 2025
Quarterly results filed (8-K) Earnings
—
August 1, 2025
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function Trial Milestone
Phase 1
May 21, 2025
8-K filed: Acquisition completed, Leadership change, Other event Corporate
—
May 14, 2025
Quarterly results filed (8-K) Earnings
—
April 21, 2025
8-K filed: Material agreement, Other event Corporate
—
December 18, 2024
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005 Trial Milestone
Phase 1
August 31, 2024
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 Trial Milestone
Phase 1
August 13, 2024
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU Trial Milestone
Phase 2
June 29, 2023
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Trial Milestone
Phase 2
December 1, 2022
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants Trial Milestone
Phase 1
June 30, 2022
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.